{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Frefractory-resistant-cmv-in-hct-recipients-fEX0vLS3","width":444,"version":"1.0","type":"rich","title":"Treatment of Refractory/Resistant CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/1c319006-f149-4d0b-b70b-2153e33a9fa1/100847_cmv_tandem_ss3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/147d4dc7-f923-4948-8f0d-8a2c721ff441\" height=\"200\" width=\"100%\" title=\"Treatment of Refractory/Resistant CMV in HCT Recipients: Optimizing Transplant Outcomes Through Contemporary CMV Management\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"There have been major advances in the management of cytomegalovirus (CMV) infection, one of the most significant infectious complications after hematopoietic cell transplant (HCT). In this podcast, featuring curated audio from a live satellite symposium, experts Roy F. Chemaly, MD, MPH, FIDSA, FACP, FESCMID, and Marcus Pereira, MD, MPH, FAST, discuss considerations for CMV treatment in HCT recipients and examine treatment options for refractory/resistant CMV."}